Annovis Bio Files Patent for New Composition of Matter for Buntanetap

[Canddy]

Interesting....see the fourth (4th) paragraph...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

This patent covers novel crystalline forms of buntanetap and their use for treating and/or preventing various neurodegenerative conditions. Crystalline forms offer significant advantages over less structured forms, including better solubility and stability. The most stable crystal form of buntanetap (CAS# 3032752-92-1) has been selected as the new lead compound for animal bridge studies and for developing a manufacturing process. The bridge studies were submitted to the FDA and will be discussed in July. The goal is to continue development of our drug and file the NDA with the new crystal form.

“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company. This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug's properties, ultimately providing greater benefits to our patients,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.

A composition of matter patent comes with protection for the new buntanetap crystalline form and all its uses for a 20-year term. The composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug because it provides adequate runway to develop a drug and bring it to market.

About Buntanetap

Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This action improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients.

About Annovis Bio, Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit annovisbio.com and follow us on LinkedIn, YouTube, and X.

[park_bear]

They already do have an existing composition of matter patent.

The big reveal coming up on Tuesday.

[eschneid in reply to park_bear]

PB...,.,. ..... . How about a normal reveal with a big result!!

[WinnieThePoo in reply to eschneid]

They're already 3 months, a data cleanse and 3 missed deadlines away from a normal reveal. And my guess is it will be similar to AD. Not quite nothing but hugely disappointing. More bigger longer trials needed and they have no cash.Sadly I don't see me queuing at the pharmacy for this one

Now generic liraglutide...

‘Skinny jabs’: weight-loss drugs set for new boom as generic versions emerge theguardian.com/business/ar...

[eschneid in reply to WinnieThePoo]

Thanks Rich.............definitely grinds us down a bit at a time all the mediocre trials.... unless you're a mouse, worm or monkey.